Clinical efficacy of ofloxacin in lower respiratory tract infections. A multicentre study.

Abstract:

:A multicentre clinical trial was carried out to determine the activity and tolerability of ofloxacin in the treatment of lower respiratory tract infections. 667 patients were randomly allocated to 1 of 3 different twice daily dosage regimens: 400 mg (245 patients), 600 mg (211) or 800 mg (211). The mean duration of treatment was 8.77 +/- 2.62 days. Satisfactory overall clinical results (i.e. cured or improved) were obtained in 612 of 667 patients (91.8%). Eradication of pathogens was achieved for 279 of 354 isolated strains (78.8%). Side effects were observed in 31 patients and consisted of gastrointestinal disturbance (22), skin rash (1), neurological disturbance (3) and others (5). No significant alteration of haematological parameters was reported.

journal_name

Drugs

journal_title

Drugs

authors

Grassi C,Gialdroni Grassi G,Mangiarotti P

doi

10.2165/00003495-198700341-00017

subject

Has Abstract

pub_date

1987-01-01 00:00:00

pages

80-2

eissn

0012-6667

issn

1179-1950

journal_volume

34 Suppl 1

pub_type

临床试验,杂志文章,随机对照试验

相关文献

DRUGS文献大全
  • Steroid-refractory severe ulcerative colitis: what are the available treatment options?

    abstract::Approximately 15% of patients with ulcerative colitis will experience a severe episode requiring hospitalization. Although intravenous corticosteroids are the current first-line therapy for these patients, about 30% of patients do not respond to corticosteroids and require either an alternative anti-inflammatory agent...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200868090-00001

    authors: Moss AC,Peppercorn MA

    更新日期:2008-01-01 00:00:00

  • Immunotherapy Against Gliomas: is the Breakthrough Near?

    abstract::Immunotherapeutic approaches have been, and continue to be, aggressively investigated in the treatment of infiltrating gliomas. While the results of late-phase clinical studies have been disappointing in this disease space thus far, the success of immunotherapies in other malignancies as well as the incremental gains ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-01203-z

    authors: Lukas RV,Wainwright DA,Horbinski CM,Iwamoto FM,Sonabend AM

    更新日期:2019-11-01 00:00:00

  • Renal protection in hypertensive patients: selection of antihypertensive therapy.

    abstract::Hypertension is common in chronic renal disease and is a risk factor for the faster progression of renal damage, and reduction of blood pressure (BP) is an efficient way of preventing or slowing the progression of this damage. International guidelines recommend lowering BP to 140/90 mm Hg or less in patients with unco...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200565002-00005

    authors: Wenzel RR

    更新日期:2005-01-01 00:00:00

  • Improving fluorouracil chemotherapy with novel orally administered fluoropyrimidines.

    abstract::During the 40 years since the initial synthesis of fluorouracil, there have been many attempts to improve fluoropyrimidine chemotherapy. These have included the utilisation of different schedules of fluorouracil administration, modulation of the metabolism of fluorouracil with other drugs to increase its therapeutic b...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199958003-00016

    authors: Diasio RB

    更新日期:1999-01-01 00:00:00

  • The memory clinic. A new approach to the detection of early dementia.

    abstract::Dementia is commonly diagnosed at a time of major domestic breakdown, when symptoms are severe and family and community patience has been eroded. In order to encourage early referral and identification of patients with treatable conditions, a Memory Clinic is held at the University Hospital in Cardiff. The clinic prov...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198700332-00016

    authors: Bayer AJ,Pathy MS,Twining C

    更新日期:1987-01-01 00:00:00

  • Peramivir: A Review in Uncomplicated Influenza.

    abstract::Intravenous peramivir (Alpivab™; Rapivab®; Rapiacta®; PeramiFlu®), the most recent globally approved inhibitor of influenza neuraminidase, is indicated for the treatment of uncomplicated influenza in adults and children from the age of 2 years. This article, written from an EU perspective, reviews the clinical use of ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-018-0981-8

    authors: Scott LJ

    更新日期:2018-09-01 00:00:00

  • Drug treatment of scleroderma.

    abstract::Scleroderma or systemic sclerosis is a rare condition with many clinical manifestations including Raynaud's phenomenon. As with many other rarely encountered diseases, drug therapy for scleroderma is often empirical with little evidence in the form of randomised controlled trials to aid drug choice. Raynaud's phenomen...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200161030-00008

    authors: Leighton C

    更新日期:2001-01-01 00:00:00

  • Optimal pharmacological therapy for community-acquired pneumonia: the role of dual antibacterial therapy.

    abstract::The optimal pharmacological therapy of community-acquired pneumonia (CAP) is one of the most ardently debated issues in medicine. Presently, most guidelines recommend either a fluoroquinolone alone or dual therapy with a third-generation cephalosporin plus a macrolide in patients hospitalised with CAP, but few provide...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200565140-00004

    authors: Epstein BJ,Gums JG

    更新日期:2005-01-01 00:00:00

  • Cibenzoline. A review of its pharmacological properties and therapeutic potential in arrhythmias.

    abstract::Cibenzoline is a class I antiarrhythmic drug with limited class III and IV activity which can be administered orally or intravenously. An elimination half-life of about 8 to 12 hours permits twice daily administration, although age and renal function must be considered when determining dosage. Cibenzoline has some act...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199243050-00008

    authors: Harron DW,Brogden RN,Faulds D,Fitton A

    更新日期:1992-05-01 00:00:00

  • Candesartan cilexetil: an update of its use in essential hypertension.

    abstract:UNLABELLED:Candesartan cilexetil is converted to the angiotensin II receptor antagonist candesartan during absorption from the gastrointestinal tract. The selective and competitive binding of candesartan to the angiotensin II type 1 (AT(1)) receptor prevents binding of angiotensin II, a key mediator in the renin-angiot...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200262080-00016

    authors: Easthope SE,Jarvis B

    更新日期:2002-01-01 00:00:00

  • Correction to: Delafloxacin: A Review in Acute Bacterial Skin and Skin Structure Infections.

    abstract::The original article can be found online. ...

    journal_title:Drugs

    pub_type: 已发布勘误

    doi:10.1007/s40265-020-01407-8

    authors: Scott LJ

    更新日期:2020-09-01 00:00:00

  • Practical treatment recommendations for the safe use of anaesthetics.

    abstract::General anaesthesia is the reversible depression of central nervous system function. There is still no agreement over what constitutes depth of anaesthesia, and the clinical anaesthetist must thus titrate drug input according to clinical signs (heart rate, blood pressure, somatic movement, autonomic responses). The po...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199243010-00006

    authors: Sear JW

    更新日期:1992-01-01 00:00:00

  • Antirheumatic drugs: clinical pharmacological and therapeutic aspects.

    abstract::There are many current concepts of the pathogenesis of rheumatic diseases which incorporate immunological, infectious and hereditary factors. Rheumatic diseases may sometimes become apparent after trauma, be associated with certain diseases and may be induced by nerve damage and serum sickness. Systemic lupuserythemat...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-197510050-00008

    authors: Smyth CJ,Bravo JF

    更新日期:1975-01-01 00:00:00

  • Sorbitol, myo-inositol and sodium-potassium ATPase in diabetic peripheral nerve.

    abstract::Slowing of nerve conduction, a hallmark of both experimental and human diabetic neuropathy, is improved or corrected by aldose reductase inhibitors such as sorbinil. Animal experiments suggest that a myo-inositol-related defect in nerve sodium-potassium adenosine triphosphatase (ATPase) is responsible for the acute re...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198600322-00004

    authors: Greene DA

    更新日期:1986-01-01 00:00:00

  • Nateglinide.

    abstract::Nateglinide is a novel D-phenylalanine derivative that inhibits ATP-sensitive K+ channels in pancreatic beta-cells in the presence of glucose and thereby stimulates the prandial release of insulin. Nateglinide reduces fasting and mealtime blood glucose levels in animals, healthy volunteers, and patients with type 2 (n...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200060030-00007

    authors: Dunn CJ,Faulds D

    更新日期:2000-09-01 00:00:00

  • Adverse effects and drug interactions of antithrombotic agents used in prevention of ischaemic stroke.

    abstract::Stroke is the third most common cause of death in the US. Primary prevention of stroke can be achieved by control of risk factors including hypertension, diabetes mellitus, elevated cholesterol levels and smoking. Approximately one-third of all ischaemic strokes occur in patients with a history of stroke or transient ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200565040-00003

    authors: Weinberger J

    更新日期:2005-01-01 00:00:00

  • Trimetrexate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of Pneumocystis carinii pneumonia.

    abstract::Trimetrexate is a folinic acid analogue structurally related to methotrexate, whose primary mechanism of action is believed to be inhibition of dihydrofolate reductase. This reduces the production of DNA and RNA precursors and leads to cell death. Trimetrexate is lipophilic and can passively diffuse across cell membra...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199549040-00007

    authors: Fulton B,Wagstaff AJ,McTavish D

    更新日期:1995-04-01 00:00:00

  • Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.

    abstract:UNLABELLED:Patients with beta-thalassaemia and other transfusion-dependent diseases develop iron overload from chronic blood transfusions and require regular iron chelation to prevent potentially fatal iron-related complications. The only iron chelator currently widely available is deferoxamine, which is expensive and ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199958030-00021

    authors: Barman Balfour JA,Foster RH

    更新日期:1999-09-01 00:00:00

  • Cholinesterase inhibitors for Alzheimer's disease.

    abstract::Alzheimer's disease (AD) is the most common age-related neurodegenerative disease and has become an urgent public health problem in most areas of the world. Substantial progress has been made in understanding the basic neurobiology of AD and, as a result, new drugs for its treatment have become available. Cholinestera...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200161010-00005

    authors: Grutzendler J,Morris JC

    更新日期:2001-01-01 00:00:00

  • Capecitabine.

    abstract::Capecitabine is an orally administered fluoropyrimidine carbamate used for the treatment of paclitaxel- or anthracycline-refractory breast cancer. Capecitabine is metabolised via a 3-step process to the active agent fluorouracil. The final step of this process occurs preferentially in malignant tissue. In patients wit...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199958010-00006

    authors: Dooley M,Goa KL

    更新日期:1999-07-01 00:00:00

  • Lemborexant: First Approval.

    abstract::Lemborexant (DAYVIGO™) is an orally administered, dual orexin receptor (OXR) antagonist that exhibits reversible competitive antagonism at OXR1 and OXR2 (> affinity at OXR2) that was discovered and developed by Eisai Inc. for the treatment of adult patients with insomnia. In December 2019, lemborexant received its fir...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01276-1

    authors: Scott LJ

    更新日期:2020-03-01 00:00:00

  • Modified Regulatory Pathways to Approve Generic Drugs in the US and a Systematic Review of Their Outcomes.

    abstract:BACKGROUND:Generic drugs are approved on the basis of pharmaceutical equivalence and bioequivalence. Some drug products have unique structural or functional attributes, necessitating modified approaches to bioequivalence determinations. OBJECTIVE:The aim of this systematic review was to identify studies that evaluated...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-015-0382-1

    authors: Kesselheim AS,Polinski JM,Fulchino LA,Isaman DL,Gagne JJ

    更新日期:2015-04-01 00:00:00

  • Drug-resistant tuberculosis: what are the treatment options?

    abstract::Drug-resistant tuberculosis (DR-TB) is an emerging global health threat as treatment involves complex multiple drug regimens, which are longer and more toxic than standard therapy and yet have worse outcomes. In the presence of resistance to one or more first-line drugs, an alternative regimen should be designed. A ma...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/11585440-000000000-00000

    authors: Albanna AS,Menzies D

    更新日期:2011-05-07 00:00:00

  • Letermovir: First Global Approval.

    abstract::Letermovir (Prevymis™) is an orally or intravenously administered cytomegalovirus (CMV) DNA terminase complex inhibitor being developed by Merck & Co., Inc., under a global license from AiCuris Anti-infective Cures GmbH. Letermovir has been approved in Canada and the USA for the prophylaxis of CMV infection and diseas...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-017-0860-8

    authors: Kim ES

    更新日期:2018-01-01 00:00:00

  • Phentermine and topiramate extended release (Qsymia™): first global approval.

    abstract::Vivus' proprietary oral capsule containing phentermine and extended-release (ER) topiramate has been approved in the US for the treatment of obesity. Phentermine is an appetite suppressant, while topiramate is an anti-epileptic medication. The once-daily formulation, known as Qsymia™, is designed to produce weight los...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/11640860-000000000-00000

    authors: Cameron F,Whiteside G,McKeage K

    更新日期:2012-10-22 00:00:00

  • Pegaspargase: A Review in Acute Lymphoblastic Leukaemia.

    abstract::Pegaspargase (Oncaspar®), a pegylated form of native Escherichia coli-derived L-asparaginase (hereafter referred as E. coliL-asparaginase), is indicated in the USA and EU for the treatment of acute lymphoblastic leukaemia (ALL) as a component of multi-agent chemotherapy in paediatric and adult patients. Relative to E....

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-01120-1

    authors: Heo YA,Syed YY,Keam SJ

    更新日期:2019-05-01 00:00:00

  • A randomised controlled study of propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis.

    abstract::74 cirrhotic patients with a history of variceal or gastric bleeding were randomly assigned to treatment with propranolol (40 to 360 mg/day) or placebo. The patients were all in good condition and doses of propranolol were titrated until a 25% reduction in heart rate was achieved. After 2 years, the cumulative percent...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-198900372-00006

    authors: Lebrec D,Poynard T,Bernuau J,Bercoff E,Nouel O,Capron JP,Poupon R,Bouvry M,Rueff B,Benhamou JP

    更新日期:1989-01-01 00:00:00

  • Postoperative ileus: progress towards effective management.

    abstract::The pathogenesis of postoperative ileus (PI) is multifactorial, and includes activation of inhibitory reflexes, inflammatory mediators and opioids (endogenous and exogenous). Accordingly, various strategies have been employed to prevent PI. As single-modality treatment, continuous postoperative epidural analgesia incl...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200262180-00004

    authors: Holte K,Kehlet H

    更新日期:2002-01-01 00:00:00

  • Transdermal clonidine. A preliminary review of its pharmacodynamic properties and therapeutic efficacy.

    abstract::The clonidine transdermal therapeutic system (TTS) is a cutaneous delivery device which provides therapeutically effective doses of clonidine at a constant rate over 7 days. In clinical trials it reduces blood pressure in patients with mild to moderate hypertension as effectively as oral clonidine but with greater sta...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198835020-00003

    authors: Langley MS,Heel RC

    更新日期:1988-02-01 00:00:00

  • Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia.

    abstract::Alfuzosin, a new quinazoline derivative, acts as a selective and competitive antagonist of alpha 1-adrenoceptor-mediated contraction of prostatic, prostatic capsule, bladder base and proximal urethral smooth muscle, thereby reducing the tone of these structures. Consequently, urethral pressure and resistance, bladder ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199345030-00008

    authors: Wilde MI,Fitton A,McTavish D

    更新日期:1993-03-01 00:00:00